Article | Published:

Regulating anxiety with extrasynaptic inhibition

Nature Neuroscience volume 18, pages 14931500 (2015) | Download Citation

  • A Corrigendum to this article was published on 25 November 2015

This article has been updated


Aversive experiences can lead to complex behavioral adaptations including increased levels of anxiety and fear generalization. The neuronal mechanisms underlying such maladaptive behavioral changes, however, are poorly understood. Here, using a combination of behavioral, physiological and optogenetic approaches in mouse, we identify a specific subpopulation of central amygdala neurons expressing protein kinase C δ (PKCδ) as key elements of the neuronal circuitry controlling anxiety. Moreover, we show that aversive experiences induce anxiety and fear generalization by regulating the activity of PKCδ+ neurons via extrasynaptic inhibition mediated by α5 subunit-containing GABAA receptors. Our findings reveal that the neuronal circuits that mediate fear and anxiety overlap at the level of defined subpopulations of central amygdala neurons and demonstrate that persistent changes in the excitability of a single cell type can orchestrate complex behavioral changes.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 05 October 2015

    In the version of this article initially published, the grant number for U.R. was given as R01MH80006 instead of R01MH080006 and grants to J.M.C. from the National Institute of Neurological Disorders and Stroke (R01NS076517) and the National Institute of Mental Health (R01MH096463), US National Institutes of Health, were missing. The error has been corrected in the HTML and PDF versions of the article.


NCBI Reference Sequence


  1. 1.

    , , & Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety. Neuropsychopharmacology 35, 105–135 (2010).

  2. 2.

    If it reduces stress (hormones), do it!. Horm. Behav. 54, 582–583 (2008).

  3. 3.

    et al. Classical fear conditioning in the anxiety disorders: a meta-analysis. Behav. Res. Ther. 43, 1391–1424 (2005).

  4. 4.

    , & The bed nucleus of the stria terminalis mediates inter-individual variations in anxiety and fear. J. Neurosci. 29, 10357–10361 (2009).

  5. 5.

    Emotion circuits in the brain. Annu. Rev. Neurosci. 23, 155–184 (2000).

  6. 6.

    , & Neuronal circuits for fear and anxiety. Nat. Rev. Neurosci. 16, 317–331 (2015).

  7. 7.

    , , & Controlling the elements: an optogenetic approach to understanding the neural circuits of fear. Biol. Psychiatry 71, 1053–1060 (2012).

  8. 8.

    et al. Encoding of conditioned fear in central amygdala inhibitory circuits. Nature 468, 277–282 (2010).

  9. 9.

    et al. Genetic dissection of an amygdala microcircuit that gates conditioned fear. Nature 468, 270–276 (2010).

  10. 10.

    , & Central amygdala activity during fear conditioning. J. Neurosci. 31, 289–294 (2011).

  11. 11.

    et al. Experience-dependent modification of a central amygdala fear circuit. Nat. Neurosci. 16, 332–339 (2013).

  12. 12.

    & New perspectives in basal forebrain organization of special relevance for neuropsychiatric disorders: the striatopallidal, amygdaloid, and corticopetal components of substantia innominata. Neuroscience 27, 1–39 (1988).

  13. 13.

    et al. Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature 471, 358–362 (2011).

  14. 14.

    et al. Distinct extended amygdala circuits for divergent motivational states. Nature 496, 224–228 (2013).

  15. 15.

    , , & Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14, 149–167 (1985).

  16. 16.

    & Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors. Nat. Rev. Neurosci. 6, 215–229 (2005).

  17. 17.

    , & Integration of quanta in cerebellar granule cells during sensory processing. Nature 428, 856–860 (2004).

  18. 18.

    , & GABA uptake regulates cortical excitability via cell type-specific tonic inhibition. Nat. Neurosci. 6, 484–490 (2003).

  19. 19.

    et al. Distinct functional and pharmacological properties of tonic and quantal inhibitory postsynaptic currents mediated by gamma-aminobutyric acid(A) receptors in hippocampal neurons. Mol. Pharmacol. 59, 814–824 (2001).

  20. 20.

    , , & Tonically active GABAA receptors in hippocampal pyramidal neurons exhibit constitutive GABA-independent gating. Mol. Pharmacol. 71, 539–548 (2007).

  21. 21.

    et al. GABA-independent GABAA receptor openings maintain tonic currents. J. Neurosci. 33, 3905–3914 (2013).

  22. 22.

    & Extrasynaptic GABAA receptors: their function in the CNS and implications for disease. Neuron 73, 23–34 (2012).

  23. 23.

    , , , & Novel subunit-specific tonic GABA currents and differential effects of ethanol in the central amygdala of CRF receptor-1 reporter mice. J. Neurosci. 33, 3284–3298 (2013).

  24. 24.

    & Training-induced changes in the expression of GABAA-associated genes in the amygdala after the acquisition and extinction of Pavlovian fear. Eur. J. Neurosci. 26, 3631–3644 (2007).

  25. 25.

    et al. Altered GABA transmission in a mouse model of increased trait anxiety. Neuroscience 183, 71–80 (2011).

  26. 26.

    et al. Selective influence on contextual memory: physiochemical properties associated with selectivity of benzodiazepine ligands at GABAA receptors containing the alpha5 subunit. J. Med. Chem. 51, 3788–3803 (2008).

  27. 27.

    et al. PWZ-029, a compound with moderate inverse agonist functional selectivity at GABAA receptors containing α5 subunits, improves passive, but not active, avoidance learning in rats. Brain Res. 1208, 150–159 (2008).

  28. 28.

    et al. Gabra5-gene haplotype block associated with behavioral properties of the full agonist benzodiazepine chlordiazepoxide. Behav. Brain Res. 233, 474–482 (2012).

  29. 29.

    , & Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 308, 245–248 (2005).

  30. 30.

    , , & Central amygdala PKC-delta neurons mediate the influence of multiple anorexigenic signals. Nat. Neurosci. 17, 1240–1248 (2014).

  31. 31.

    & Shunting inhibition modulates neuronal gain during synaptic excitation. Neuron 38, 433–445 (2003).

  32. 32.

    & The Mouse Brain in Stereotaxic Coordinates (Academic, New York, 1997).

  33. 33.

    , , , & GABAA receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 101, 815–850 (2000).

  34. 34.

    et al. Patterns of mRNA and protein expression for 12 GABAA receptor subunits in the mouse brain. Neuroscience 236, 345–372 (2013).

  35. 35.

    et al. Cre-lox-regulated conditional RNA interference from transgenes. Proc. Natl. Acad. Sci. USA 101, 10380–10385 (2004).

Download references


We thank all members of the Lüthi laboratory for discussions and critical comments on the manuscript. In particularly, we thank P. Tovote, S. Wolff, S. Ciocchi, F. Grenier, J. Gruendemann, C. Müller, K. Bylund and A. Loche for comments and for technical support, and W. Sieghart (Medical University of Vienna) and D. Anderson (California Institute of Technology) for antibodies and mice. This work was supported by the Novartis Research Foundation, by the National Center of Competences in Research program 'SYNAPSY — The Synaptic Bases of Mental Diseases' (financed by the Swiss National Science Foundation (SNSF)) as well as by an SNSF core grant to A.L. J.P.F. was supported by a NARSAD fellowship. C.X. was supported by an EMBO Long-Term Fellowship. P.S. and L.X. were supported by the Australian National Health and Medical Research Council. U.R. was supported by grant R01MH080006 from the US National Institute of Mental Health, National Institutes of Health. Funding for J.M.C. was provided by the National Institute of Neurological Disorders and Stroke (R01NS076517) and the National Institute of Mental Health (R01MH096463), US National Institutes of Health. Y.K. and F.F. were supported by Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) Sonderforschungsbereich grant F44-17.

Author information


  1. Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.

    • Paolo Botta
    • , Lynda Demmou
    • , Milica Markovic
    • , Chun Xu
    • , Jonathan P Fadok
    • , Tingjia Lu
    •  & Andreas Lüthi
  2. University of Basel, Basel, Switzerland.

    • Paolo Botta
    • , Lynda Demmou
    •  & Milica Markovic
  3. Department of Pharmacology, Innsbruck Medical University, Innsbruck, Austria.

    • Yu Kasugai
    •  & Francesco Ferraguti
  4. Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.

    • Michael M Poe
    •  & James M Cook
  5. Queensland Brain Institute, University of Queensland, St. Lucia, Queensland, Australia.

    • Li Xu
    •  & Pankaj Sah
  6. Laboratory of Genetic Neuropharmacology, McLean Hospital and Department of Psychiatry, Harvard Medical School, Belmont, Massachusetts, USA.

    • Uwe Rudolph


  1. Search for Paolo Botta in:

  2. Search for Lynda Demmou in:

  3. Search for Yu Kasugai in:

  4. Search for Milica Markovic in:

  5. Search for Chun Xu in:

  6. Search for Jonathan P Fadok in:

  7. Search for Tingjia Lu in:

  8. Search for Michael M Poe in:

  9. Search for Li Xu in:

  10. Search for James M Cook in:

  11. Search for Uwe Rudolph in:

  12. Search for Pankaj Sah in:

  13. Search for Francesco Ferraguti in:

  14. Search for Andreas Lüthi in:


The manuscript was prepared by A.L. and P.B. Electrophysiological recordings in vitro, behavioral experiments and viral injections were performed by P.B. Pharmacology combined with single-unit recordings in freely moving animals were designed and performed by L.D. In vivo recordings from optogenetically identified neurons were performed by M.M. and J.P.F. Immunohistochemistry was accomplished by C.X. T.L. cloned the conditional shRNA plasmid. M.M.P. and J.M.C. provided the PWZ-029. L.X. tested the shRNA efficacy on α5GABAAR protein in HEK293T cells and P.S. provided the plasmid expressing shRNA. U.R. provided perfused brains of α5−/− mice and of α5fl/fl mice. All electron microscopy experiments were performed and analyzed by Y.K. and F.F.

Competing interests

In the last 3 years, U.R. has received compensation for professional services from Concert Pharmaceuticals.

Corresponding author

Correspondence to Andreas Lüthi.

Integrated supplementary information

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–10

  2. 2.

    Supplementary Methods Checklist

About this article

Publication history





Further reading